Key result
A novel Arg654His missense mutation in MyBP-C was identified in a South African proband with hypertrophic cardiomyopathy and his three adult children, though only the proband was markedly affected.
Observational
Answers are grounded in this paper and cite their sources.
Identifies a novel missense mutation (Arg654His) in MyBP-C associated with hypertrophic cardiomyopathy that does not affect the myosin or titin binding domains.
Hypertrophic cardiomyopathy is a primary cardiac disease, characterised by idiopathic myocardial hypertrophy, and is caused by defects in sarcomeric protein encoding genes. One of these genes is cardiac myosin binding protein C (MyBP-C), in which a number of splice site and duplication mutations causing HCM have been described. During mutation screening of a South African HCM population by PCR-SSCP, a missense mutation, Arg654His, was detected in one proband. Although the mutation was present in his three adult children, only the proband himself was markedly affected. This is the first report of a disease associated missense mutation in MyBP-C which does not affect the myosin or titin binding domains.
No takes yet. Share an insight, caveat, or question.
Moolman‐Smook et al. (1998) conducted an observational in Hypertrophic cardiomyopathy. Arg654His missense mutation in MyBP-C was evaluated on Hypertrophic cardiomyopathy phenotype. A novel Arg654His missense mutation in MyBP-C was identified in a South African proband with hypertrophic cardiomyopathy and his three adult children, though only the proband was markedly affected.
Synapse has enriched 10 related papers. Consider them for comparative context: